Related Experiment Video
Updated: May 12, 2026
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
Clinical experience using trofinetide in Rett syndrome and related MECP2 diagnosis at the children's hospital of
Erin O'Connor Prange1, Dennis Fleysh1, Keerthana Reddy1
1Division of Neurology, Children's Hospital of Philadelphia, Philadelphia, PA, United States.
Introduction:
Rett syndrome (RTT) is a rare neurodevelopmental disorder primarily caused by pathogenic variants in the MECP2 gene. Trofinetide (Daybue) became the first FDA-approved medication for RTT in March 2023. This study evaluates the real-world effectiveness and side effect profile of Trofinetide in 55 individuals (50 females, 5 males) with RTT or MECP2-related neurodevelopmental disorders over a 12-month period.
Methods:
Data was collected through clinic assessments and caregiver reports.
Results:
Results demonstrated that 75.9% of individuals experienced some improvement in RTT symptoms by caregiver report, particularly in engagement, communication, and motor skills. The side effect profile was better than the phase 3 trials with only 48.1% reporting diarrhea and 16.7% experiencing vomiting.
Discussion:
Overall, the findings support the effectiveness of trofinetide in the RTT population and suggests potential effectiveness in the broader MECP2 population including males and those with atypical presentations. The data highlights the need for further work to determine long-term benefits in the full spectrum of MECP2 related disorders. Finally, the study highlights the importance of titration, individualized dosing and side effect management to improve retention and outcomes.
